Long-Term Patency of Hemashield Vascular Grafts Used for Middle Hepatic Vein Reconstruction During Living-Donor Liver Transplantation: A Single-Center Korean Experience
Annals of Transplantation · 2026
DOI: 10.12659/aot.951216 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Annals of Transplantation, 2026. Verfasst von Dae Hyeon Won und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seo…. Hauptthemen laut MEDLINE: Liver Transplantation, Hepatic Veins, Vascular Patency, Blood Vessel Prosthesis. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND The availability of homologous vein allografts is limited. Therefore, prosthetic vascular grafts can be used as alternatives for middle hepatic vein (MHV) reconstruction during living-donor liver transplantation (LDLT). This study evaluated the short- and long-term patency of MHV reconstructions using Hemashield vascular grafts and assessed their effect on post-transplant survival. MATERIAL AND METHODS This retrospective observational study included 149 adult LDLT recipients who underwent MHV reconstruction using Hemashield grafts at a single institution. Graft patency and survival outcomes were assessed over long-term follow-up. RESULTS The mean recipient age was 56.2±7.7 years, and the mean graft-to-recipient weight ratio was 1.06±0.25. V5 reconstruction was achieved through single, double, and triple anastomoses in 111, 32, and 2 patients, respectively. V8 reconstruction in 116, 20, and one patient was achieved through single, double, and triple anastomoses, respectively. In 100 and 49 cases, we used Hemashield grafts with diameters of 10 mm and 12 mm, respectively. Three patients (2.0%) developed early thrombosis that necessitated stent placement. The cumulative conduit occlusion-free survival rates were 81.0% at 3 months, 57.9% at 1 year, 48.7% at 3 years, and 43.8% at 5 years. Overall patient survival rates were 95.3% at 1 year, 89.1% at 3 years, and 85.7% at 5 years. No cases of graft migration or conduit-related infection were identified. CONCLUSIONS MHV reconstruction using Hemashield grafts demonstrated acceptable short- and long-term patency, with no migration or infection. These findings support the use of Hemashield grafts as a reliable and effective prosthetic option for MHV reconstruction during LDLT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
ORCID-Profile: Dae Hyeon Won, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Young-In Yoon, Sung-Gyu Lee
Zitieren
APA
Won, D. H., Hwang, S., Ahn, C. S., Moon, D. B., Ha, T. Y., Song, G. W., Jung, D. H., Park, G. C., Kang, W. H., Yoon, Y. I., & Lee, S. G. (2026). Long-Term Patency of Hemashield Vascular Grafts Used for Middle Hepatic Vein Reconstruction During Living-Donor Liver Transplantation: A Single-Center Korean Experience. Annals of Transplantation. https://doi.org/10.12659/aot.951216
Vancouver
Won DH, Hwang S, Ahn CS, Moon DB, Ha TY, Song GW, et al. Long-Term Patency of Hemashield Vascular Grafts Used for Middle Hepatic Vein Reconstruction During Living-Donor Liver Transplantation: A Single-Center Korean Experience. Annals of Transplantation. 2026. doi:10.12659/aot.951216
BibTeX
@article{Won2026,
author = {Won, Dae Hyeon and Hwang, Shin and Ahn, Chul-Soo and Moon, Deok-Bog and Ha, Tae-Yong and Song, Gi-Won and Jung, Dong-Hwan and Park, Gil-Chun and Kang, Woo-Hyoung and Yoon, Young-In and Lee, Sung-Gyu},
title = {Long-Term Patency of Hemashield Vascular Grafts Used for Middle Hepatic Vein Reconstruction During Living-Donor Liver Transplantation: A Single-Center Korean Experience},
journal = {Annals of Transplantation},
year = {2026},
doi = {10.12659/aot.951216}
}
EUVIMED